According to an order entered today, all Pradaxa cases in the federal court system, now pending and filed in the future, will be consolidated in front of Judge Herndon in the Southern District of Illinois.
Despite objections by the defense and proposals of alternative venues, Judge Heyburn and the judicial panel agreed with many plaintiffs, including TorHoerman Law, that proper venue for the Pradaxa litigation should be the Southern District of Illinois.
Pradaxa (dabigitran) was introduced in late 2010 for the prevention of stroke among patients with non-valvular atrial fibrillation. Pradaxa was designed to thin blood and reduce blood clots, which can cause strokes.Yet, in the less than two years since its release, Boehringer Ingelheim’s anticoagulant Pradaxa is already beginning to create considerable controversy.
Recent studies have found that an increasing number of people who have suffered fatal or severe bleeding events may have done so as result of their use of Pradaxa. Many of these sufferers are elderly patients, patients whose age provides convenient alternative explanations for drug companies who are accused of harming patients.
From January 1, 2004 to March 31, 2012, nearly 15,000 serious adverse event reports have identified Pradaxa as the primary suspect drug.
TorHoerman Law has two cases currently pending before Judge Herndon and has been actively pursuing the litigation – including successfully defeating a defendant’s motion to dismiss.
We at TorHoerman Law look forward to continuing our active pursuit of this case in front of Judge Herndon, right here close to home.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.